<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="4603">
  <stage>Registered</stage>
  <submitdate>25/11/2013</submitdate>
  <approvaldate>25/11/2013</approvaldate>
  <nctid>NCT01998828</nctid>
  <trial_identification>
    <studytitle>Safety and Efficacy of Momelotinib in Subjects With Polycythemia Vera or Essential Thrombocythemia</studytitle>
    <scientifictitle>A Phase 2, Open-label, Randomized Study to Evaluate the Safety and Efficacy of Momelotinib in Subjects With Polycythemia Vera or Essential Thrombocythemia</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>2013-004105-11</secondaryid>
    <secondaryid>GS-US-354-0101</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Polycythemia Vera</healthcondition>
    <healthcondition>Essential Thrombocythemia</healthcondition>
    <conditioncode>
      <conditioncode1>Blood </conditioncode1>
      <conditioncode2>Haematological diseases</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Blood </conditioncode1>
      <conditioncode2>Other blood disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Momelotinib

Experimental: Momelotinib 100 mg PV - Participants with polycythemia vera will receive 100 mg of momelotinib.

Experimental: Momelotinib 200 mg PV - Participants with polycythemia vera will receive 200 mg of momelotinib.

Experimental: Momelotinib 100 mg ET - Participants with essential thrombocythemia will receive 100 mg of momelotinib.

Experimental: Momelotinib 200 mg ET - Participants with essential thrombocythemia will receive 200 mg of momelotinib.


Treatment: drugs: Momelotinib
Momelotinib tablet administered orally once daily

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Overall response rate - For the PV Cohort, overall response rate (ORR) is defined as the proportion of participants with all of the following at some point during the treatment period:
Hematocrit &lt; 45% in the absence of phlebotomy that lasts at least 4 weeks
White blood cell (WBC) count &lt; 10 x 10^9/L that lasts at least 4 weeks
Platelet count = 400 x 10^9/L that lasts at least 4 weeks
Resolution of palpable splenomegaly that lasts at least 4 weeks
For the ET Cohort, overall response rate is defined as the proportion of participants with all of the following at some point during the treatment period:
WBC count &lt; 10 x 10^9/L that lasts at least 4 weeks
Platelet count = 400 x 10^9/L that lasts at least 4 weeks
Resolution of palpable splenomegaly that lasts at least 4 weeks</outcome>
      <timepoint>Up to 24 weeks</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Confirmed overall response rate - Confirmed overall response rate is defined as the proportion of participants who meet all the criteria listed for the primary endpoints of PV or ET, sustained for at least 12 weeks.</outcome>
      <timepoint>Up to 24 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Proportion of participants with hematocrit &lt; 45% in the absence of phlebotomy that lasts at least 4 weeks</outcome>
      <timepoint>Up to 24 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Proportion of participants with WBC &lt; 10 x 10^9/L that lasts at least 4 weeks</outcome>
      <timepoint>Up to 24 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Proportion of participants with platelet count = 400 x 10^9/L that lasts at least 4 weeks</outcome>
      <timepoint>Up to 24 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Proportion of participants with resolution of palpable splenomegaly that lasts at least 4 weeks</outcome>
      <timepoint>Up to 24 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Proportion of participants with = 10 point decrease in modified Myeloproliferative Neoplasm Symptom Assessment Form Total Symptom Score (MPNSAF TSS) compared to baseline that lasts at least 12 weeks</outcome>
      <timepoint>Up to 24 weeks</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Diagnosis of either PV or ET as defined by the 2008 World Health Organization (WHO)
             Diagnostic Criteria

          -  Requires treatment for PV or ET, in the opinion of the study investigator

          -  Intolerant of, resistant to, or refuses current or available treatment for PV or ET

          -  Direct bilirubin = 2.0 x upper limit of the normal range (ULN)

          -  Aspartate transaminase (AST) and alanine transaminase (ALT) = 3 x ULN

          -  Calculated creatinine clearance (CrCl) of = 45 mL/min

          -  Life expectancy &gt; 24 weeks

          -  Male subjects and female subjects of childbearing potential who engage in heterosexual
             intercourse must agree to use protocol specified method(s) of contraception

          -  Females who are nursing must agree to discontinue nursing before the first dose of
             study drug

          -  Able to comprehend and willing to sign informed consent form</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Prior splenectomy

          -  Uncontrolled intercurrent illness, per protocol

          -  Known positive status for human immunodeficiency virus (HIV)

          -  Chronic active or acute viral hepatitis A, B, or C infection, or hepatitis B or C
             carrier

          -  Myeloproliferative neoplasm-directed therapy, other than aspirin, hydroxyurea,
             anagrelide, and/or phlebotomy, within 21 days prior to the first dose of study drug

          -  Anagrelide within 7 days prior to the first dose of study drug

          -  Presence of peripheral neuropathy = Grade 2

          -  Unwilling or unable to take oral medication

          -  Prior use of a JAK1 or JAK2 inhibitor

          -  Use of strong CYP3A4 inducers within 1 week prior to the first dose of study drug

          -  QTc interval &gt; 450 msec, unless attributed to bundle branch block</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>1/02/2014</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>39</actualsamplesize>
    <recruitmentstatus>Terminated</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/05/2015</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>VIC</recruitmentstate>
    <hospital> - Frankston</hospital>
    <hospital> - Parkville</hospital>
    <postcode> - Frankston</postcode>
    <postcode> - Parkville</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Arizona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Mississippi</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Missouri</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Ontario</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Quebec</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Vancouver</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>La Tronche</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Nantes Cedex 1</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Paris</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Dresden</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Minden</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Gilead Sciences</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>This open-label study is to determine the safety and efficacy of momelotinib in participants
      with either polycythemia vera (PV) or essential thrombocythemia (ET) who have not yet
      received treatment with a Janus kinase (JAK) inhibitor.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01998828</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Peter Lee, MD, PhD</name>
      <address>Gilead Sciences</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>